IASO206 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia
Phase I Clinical Study on the Safety and Tolerability of IASO206 Injection in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia
This study is an open-label, single-arm early exploratory clinical study, aiming to evaluate the safety, tolerability and preliminary efficacy of IASO206 Injection (In Vivo CAR-T) in Patients with Relapsed/Refractory Autoimmune Hemolytic Anemia
調査の概要
研究の種類
入学 (推定)
段階
- フェーズ 1
連絡先と場所
研究連絡先
- 名前:Jun Shi, PhD
- 電話番号:13752253515
- メール:shijun@ihcams.ac.cn
研究連絡先のバックアップ
- 名前:Lele Zhang, PhD
- 電話番号:15811139278
- メール:zhanglele@ihcams.ac.cn
参加基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Age 18 to 75 years, gender unrestricted.
- Diagnosis of AIHA (including warm antibody type, warm-cold antibody type, cold agglutinin disease) or Evans syndrome, consistent with Chinese Expert Consensus on Diagnosis and Treatment of Autoimmune Hemolytic Anemia (2023), 2019 International Consensus for Diagnosis and Management of Autoimmune Hemolytic Anemia (Blood Rev, 2020), or Chinese Expert Consensus on Diagnosis and Treatment of Evans Syndrome (2024 Edition).
- Patients with relapsed/refractory disease after multiple lines of therapy must meet all of the following criteria: hemoglobin < 10 g/dL with clinical manifestations of hemolytic anemia; prior treatment with at least 2 immunosuppressive drugs (must include CD20 monoclonal antibody); glucocorticoid therapy for at least 3 months (excluded are patients with contraindications to glucocorticoids, severe infection, severe osteoporosis, previous fracture, or inability to tolerate glucocorticoids); cumulative dose of CD20 monoclonal antibody at least 375 mg/m² × 4, or total dose 2.0 g, or at least 6 administrations (at least 1 week apart each time).
- ECOG score ≤ 2.
- Expected survival time ≥ 12 weeks.
- Adequate organ function confirmed by laboratory tests: serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 1.5 × upper limit of normal (ULN); minimum pulmonary reserve defined as grade ≤ 1 dyspnea and oxygen saturation ≥ 93% without oxygen supplementation; creatinine clearance (estimated by Cockcroft-Gault) ≥ 45 mL/min; cardiac ejection fraction ≥ 50%, no pericardial effusion on echocardiogram (ECHO), and no clinically significant abnormal electrocardiogram (ECG).
- Subjects and their partners agree to use effective barrier or medical contraceptive measures (excluding rhythm method) from signing informed consent until 1 year after administration.
- Subjects must provide written informed consent approved by the Ethics Committee prior to initiation of screening procedures
Exclusion Criteria:
-
Subject with confirmed lymphoproliferative neoplasms.
-
Subject with secondary AIHA induced by drugs or infection.
-
Subject with congenital immunodeficiency diseases, other hereditary or acquired hemolytic diseases.
-
Subject with a history of organ or stem cell transplantation.
-
Subject with a history of organ infarction within the past 6 months.
-
Subject who have received prior BCMA-targeted therapy.
-
Subject who received plasma cell-targeted cell therapy within 3 months before screening, or in whom prior cell therapy products are still detectable in peripheral blood.
-
Subject who received any of the following treatments within the specified periods prior to study enrollment:
- Anti-CD20 monoclonal antibody < 12 weeks;
- Sutimlimab or other marketed biological products < 5 half-lives;
- Plasma exchange < 4 weeks;
- Splenectomy < 12 weeks.
-
Subject with any of the following cardiovascular diseases:
- Left ventricular ejection fraction (LVEF) ≤ 45%;
- Active heart disease or congestive heart failure (New York Heart Association [NYHA] Class III or IV);
- Severe arrhythmia requiring treatment (excluding atrial fibrillation, paroxysmal supraventricular tachycardia);
- QTcB interval ≥ 450 ms for males, ≥ 470 ms for females;
- Myocardial infarction, bypass surgery, or stent implantation within 6 months before study;
- Other cardiac diseases judged by the investigator to be unsuitable for enrollment.
-
Unstable systemic diseases judged by the investigator, including but not limited to severe hepatic or renal diseases requiring medical treatment.
-
Subject with a history of other primary malignancies within 5 years before screening, except:
- Resected and cured non-melanoma skin cancer (e.g., basal cell carcinoma);
- Cured carcinoma in situ (e.g., cervical, bladder, or breast cancer);
- Other primary cancers with no evidence of recurrence for more than 5 years after treatment.
-
Subject who underwent major surgery within 4 weeks before screening and are judged unsuitable for enrollment by the investigator.
-
Subject with uncontrolled active fungal, viral, bacterial, mycobacterial, or other infections (persistent infection-related signs/symptoms without improvement after appropriate anti-infective therapy) or infections requiring intravenous anti-infective therapy.
-
Positive hepatitis B surface antigen (HBs-Ag) or hepatitis B e antigen (HBe-Ag); positive hepatitis B e antibody (HBe-Ab) or hepatitis B core antibody (HBc-Ab) with HBV-DNA copy number above the lower limit of quantification; positive hepatitis C (HCV) antibody; positive human immunodeficiency virus (HIV) antibody; active syphilis infection (excluding those with only positive syphilis-specific antibody).
-
Subject who received live viral vaccines within 4 weeks before enrollment.
-
Subject who are participating in other interventional clinical studies during IASO206 Injection treatment with a drug half-life < 5; subject receiving active investigational drugs during the entire study period, or who intend to participate in another clinical trial, or receive treatments outside the protocol.
-
Pregnant or lactating females.
-
Subject with psychiatric disorders, disturbance of consciousness, or central nervous system diseases, including but not limited to epilepsy and Parkinson's disease.
-
Subject with hypersensitivity to components of IASO206 Injection or supportive medications required for the management of CAR-T therapy-related toxicities (e.g., tocilizumab).
-
Other conditions judged by the investigator to be unsuitable for enrollment.10. Other Information
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:なし
- 介入モデル:単一グループの割り当て
- マスキング:なし(オープンラベル)
武器と介入
参加者グループ / アーム |
介入・治療 |
|---|---|
|
実験的:IASO206
Subjects will receive a single infusion of IASO206 injection in a 3+3 dose-escalation design. Three ascending dose cohorts are planned: 1E8 TU, 3E8 TU, and 5E8 TU. In each dose cohort, the first subject will be observed for at least 3 weeks after infusion before subsequent subjects in the same cohort receive IASO206 injection. |
The third-generation self-inactivating lentiviral vector that carries a BCMA-targeted CAR. Administered in one infusion. |
この研究は何を測定していますか?
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Incidence and severity of adverse events
時間枠:Up to 3 months after IASO206 infusion
|
Assessed by CTCAE Version 5.0. |
Up to 3 months after IASO206 infusion
|
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Proportion of patients achieving response
時間枠:At Weeks 4, 8, and 12, and Months 4, 5, and 6 after IASO206 infusion
|
Response assessment is primarily assessed based on hemoglobin, and should be performed after discontinuation of glucocorticoids or other immunosuppressive therapies for at least 2 weeks. |
At Weeks 4, 8, and 12, and Months 4, 5, and 6 after IASO206 infusion
|
協力者と研究者
研究記録日
主要日程の研究
研究開始 (推定)
一次修了 (推定)
研究の完了 (推定)
試験登録日
最初に提出
QC基準を満たした最初の提出物
最初の投稿 (実際)
学習記録の更新
投稿された最後の更新 (実際)
QC基準を満たした最後の更新が送信されました
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
- IASO206CI003
個々の参加者データ (IPD) の計画
個々の参加者データ (IPD) を共有する予定はありますか?
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。